-
DPP-4 Inhibitors for the Treatment of Parkinson’s Disease (Supplement)
… responsible for the metabolism of the endogenous incretins GLP-1 and GIP, whose elevated levels in brain, we hypothesized, … sitagliptin will elevate plasma and spinal fluid levels of GLP-1 and GIP levels by a minimum of two-fold, considered to …
-
Diabetes Drug Trial Results Lay Foundation for Further Investigation
August 3, 2017
… belongs to a class of drugs, called glucagon-like peptide-1 (GLP-1) agonists, which are used to treat type 2 diabetes. It … insulin release from the pancreas by binding to the GLP-1 receptor. These same receptors also are found in the …
-
Pre-clinical Development of a Parkinson's Disease Therapy Using a Glucagon-Like Peptide (GLP)-1 Receptor Agonist
… Objective/Rationale : The Glucagon-Like-Peptide-1 (GLP-1) receptor agonist, exendin-4 (exenatide injection; brand …
-
Michael J. Fox Foundation Awards $3.8 Million to Drive Nine Industry Partnerships for Pre-Clinical Parkinson's Drug Development
July 21, 2009
… Parkinson’s disease therapy using a glucagon-like peptide (GLP-1) receptor agonist Kevin Tomaselli, PhD, Amylin … industry researchers. To date the Foundation has awarded $16.5 million total for 33 industry-led projects under the …
-
Ask the PhD: Parkinson's and the Microbiome
May 7, 2019
… through the vagus nerve and the circulatory system. A 2017 study found an association between severing the vagus … of bacteria, which have around 3 million genes. We harbor 150 times more bacterial genes in our bodies than genes in … validate targets in the gut like the hormone ghrelin and GLP-1 that could guide the development of new treatments. A …